KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Hims & Hers Health (HIMS) Research & Development: 2021-2025

Historic Research & Development for Hims & Hers Health (HIMS) over the last 4 years, with Sep 2025 value amounting to $40.6 million.

  • Hims & Hers Health's Research & Development rose 92.38% to $40.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $132.1 million, marking a year-over-year increase of 92.90%. This contributed to the annual value of $78.8 million for FY2024, which is 63.43% up from last year.
  • Latest data reveals that Hims & Hers Health reported Research & Development of $40.6 million as of Q3 2025, which was up 7.21% from $37.8 million recorded in Q2 2025.
  • Over the past 5 years, Hims & Hers Health's Research & Development peaked at $40.6 million during Q3 2025, and registered a low of $5.6 million during Q4 2021.
  • Moreover, its 3-year median value for Research & Development was $18.7 million (2024), whereas its average is $21.4 million.
  • Data for Hims & Hers Health's Research & Development shows a peak YoY soared of 102.89% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Hims & Hers Health's Research & Development stood at $5.6 million in 2021, then skyrocketed by 49.16% to $8.3 million in 2022, then soared by 61.29% to $13.4 million in 2023, then soared by 77.17% to $23.7 million in 2024, then skyrocketed by 92.38% to $40.6 million in 2025.
  • Its Research & Development stands at $40.6 million for Q3 2025, versus $37.8 million for Q2 2025 and $29.9 million for Q1 2025.